Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib

Patients have responded well to the multi-targeted tyrosine kinase inhibitor (TKI) Sunitinib in the clinic. But the severe toxic side effects associated with Sunitinib limit its therapeutic index. To improve the therapeutic index of Sunitinib, a prodrug strategy was employed to modify Sunitinib. The...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS One
Hauptverfasser: Huang, Qiang, Zhou, Changhua, Chen, Xiao, Dong, Bing, Chen, Siqi, Zhang, Ning, Liu, Yawei, Li, Anrong, Yao, Meicun, Miao, Ji, Li, Qing, Wang, Zhong
Format: Artigo
Sprache:Inglês
Veröffentlicht: Public Library of Science 2015
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4626378/
https://ncbi.nlm.nih.gov/pubmed/26513662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0141395
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge